Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ImmunoCellular Therapeutics, Ltd. | rrd379966.htm |
| EX-99 - PRESS RELEASE DATED MAY 9, 2013 - ImmunoCellular Therapeutics, Ltd. | rrd379966_39614.htm |
| Condensed Balance Sheets | ||||||||
| 3/31/2013 | 12/31/2012 | |||||||
| (unaudited) | ||||||||
|
|
|
|
|
|||||
| Cash | $ | 24,104,258 | $ | 26,216,668 | ||||
| Other current assets | 818,042 | 714,508 | ||||||
| Non current assets | 148,364 | 88,025 | ||||||
|
|
|
|
|
|||||
| $ | 25,070,664 | $ | 27,019,201 | |||||
|
|
|
|
|
|||||
| Current liabilities | $ | 1,157,888 | $ | 1,098,307 | ||||
| Warrant liabilities | 5,484,562 | 2,852,880 | ||||||
| Shareholders' equity | 18,428,214 | 23,068,014 | ||||||
|
|
|
|
|
|||||
| $ | 25,070,664 | $ | 27,019,201 | |||||
|
|
|
|
|
|||||
| Condensed Statements of Operations (unaudited) | ||||||||
| Three months | Three months | |||||||
| ended | ended | |||||||
| 3/31/2013 | 3/31/2012 | |||||||
|
|
|
|
|
|||||
| Revenue | $0 | $0 | ||||||
| Research and development | 1,415,261 | 1,998,536 | ||||||
| Stock based compensation | 164,128 | 245,107 | ||||||
| General and administrative | 769,267 | 805,798 | ||||||
|
|
|
|
|
|||||
| Loss before other expenses | (2,348,656) | (3,049,441) | ||||||
| Interest income | 6,548 | 1,034 | ||||||
| Financing expense | - | (368,524) | ||||||
| Change in fair value of warrant liabilities | (2,631,683) | (4,472,504) | ||||||
|
|
|
|
|
|||||
| Net loss | $ | (4,973,791) | $ | (7,889,435) | ||||
|
|
|
|
|
|||||
| Net loss per share, basic and diluted: | $ | (0.10) | $ | (0.21) | ||||
|
|
|
|
|
|||||